Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation
solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over
48 weeks, compared to placebo, in children (6 to 11 years old) with moderate persistent
asthma.